Navigation Links
GeoVax Labs, Inc. Announces First Quarter Financial Results
Date:5/7/2009

ATLANTA, May 7 /PRNewswire-FirstCall/ --GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta-based biotechnology company focused on development of an HIV/AIDS vaccine, today announced its financial results for the three months ended March 31, 2009.

GeoVax reported a net loss of $861,509 for the three months ended March 31, 2009, compared to $682,510 for the same period in 2008. Net losses were partially offset by grant revenues of $710,155 and $599,991 for each period, respectively, related to the Company's grant from the National Institutes of Health in support of its HIV/AIDS vaccine development activities. As of March 31, 2009, the Company reported cash balances totaling $1,970,971.

Summarized financial information is attached. Further information concerning the Company's financial position and results of operations are included in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission.

Management Commentary

Robert McNally, GeoVax's President & CEO, commented, "We are pleased with our first quarter financial results, as we continue to hold the line on our operational expenses and maintain a steady cash balance position. We are also pleased with our Phase 2a preventative AIDS human trial commencement of injections in February and are looking forward to our human therapeutic trial launch later this year."

Dr. McNally continued, "Despite the global financial crisis, we anticipate our financial position to remain steady during the year, thanks to the National Institutes of Health's (NIH) National Institutes of Allergy and Infectious Diseases (NIAID) direct grant to GeoVax towards the research and development of our vaccines program; human clinical trials support and financial assistance received from NIH-NIAID through the HIV Trials Network; and our planned use of funding provided by the common stock purchase agreement with Fusion Capital
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. GeoVax Labs, Inc. Second Quarter Financial Results and Operational Update
2. U.S. Government Awards $15 Million Grant to GeoVax Labs HIV/AIDS Vaccine Program
3. GeoVax Further Strengthens Management Team
4. GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update
5. GeoVax Labs, Inc. Information To Be Available Through Standard & Poors Market Access Program
6. GeoVax Presents Data at AIDS Vaccine 2008 Conference
7. GeoVaxs DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
8. GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update
9. GeoVax to Present at the BIO CEO & Investor Conference 2009
10. GeoVax to Webcast Its Presentation at the BIO CEO & Investor 2009 Conference
11. GeoVax Update Provided at the BIO CEO & Investor Conference 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... ... July 01, 2015 , ... ... combat pathogen transmission. CTI’ new Medical Joysticks have an impermeable molecular barrier ... have an operator control device that will increase healthcare worker safety and reduce ...
(Date:6/30/2015)... ... June 30, 2015 , ... Students and faculty from ... first half of “Integrative Biotechnology,” an applied biotechnology course team-taught by faculty members ... course combines students from both universities and is taught on both continents. , ...
(Date:6/30/2015)... June 30, 2015  NASA astronaut Kjell Lindgren , ... on his first mission to the International Space Station ... to 9 a.m. EDT Tuesday, July 7. Lindgren ... City, Russia . The interviews will be ... highlighting his mission training. To schedule an interview, ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... will provide new insights on mechanics of fecal microbiota transplantation in C. difficile ... study the microbiome of patients undergoing fecal microbiota transplantation (FMT) as a treatment ...
Breaking Biology Technology:Sanitized Medical Joysticks for a Safer and Healthier Work Environment 2Rivier University and Beijing City University Academic and Cultural Exchanges Begin 2NASA Astronaut Preps for First Space Station Mission, Available for Media Interviews 2uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 2uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 3
... Spine, LLC, a medical device company focused on developing ... degenerative disc disease, today announced a 46% sales increase ... the revenue improvement, RSB Spine Chief Executive Officer John ... rewarding considering the overall spine market contraction in 2011, ...
... Therapeutics (NYSE Amex: CXM) today announced that it is scheduled ... Annual OneMedForum Conference in San Francisco. (Logo: ... held at the Parc 55 Wyndham in San Francisco and ... at 4:00 p.m. Pacific. The 5th Annual OneMedForum ...
... the Global Probiotics Council (GPC), a committee formed by ... of the fifth annual Young Investigator Grant for Probiotics ... the amount of $50,000, to promising young researchers. This ... role of probiotics and gastrointestinal microbiota in health and ...
Cached Biology Technology:Cardium to Present at Upcoming Investor Conferences 2Fifth Cycle of Probiotics & Microbiota Research Grant Announced 2Fifth Cycle of Probiotics & Microbiota Research Grant Announced 3Fifth Cycle of Probiotics & Microbiota Research Grant Announced 4
(Date:6/17/2015)... PALM BEACH GARDENS, Fla. , June 17, ... identity management solutions, today announced that its U.are.U ... by Togo,s Eateries, Inc., ... based fast casual sandwich chain, to increase security, ... (POS). The Crossmatch fingerprint readers enable instant, non-repudiable identity ...
(Date:6/15/2015)... , June 16, 2015 According ... Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, ... to 2020" published by MarketsandMarkets, The Natural Language Processing ... a CAGR of 18.4% for the forecast period 2015-2020. ...   46 F igures spread   through 155 ...
(Date:6/10/2015)... , June 10, 2015 ... Sensor Market by Technology (Ultrasound, TOF, Structured Light, ... Electronics, Entertainment, Automotive) and by Geography - Trends ... MarketsandMarkets, the market is expected to reach $3,319.71 ... 25.51% between 2015 and 2020. Browse ...
Breaking Biology News(10 mins):Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 2Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 3Natural Language Processing Market Worth $13.4 Billion by 2020 2Natural Language Processing Market Worth $13.4 Billion by 2020 3Natural Language Processing Market Worth $13.4 Billion by 2020 4Natural Language Processing Market Worth $13.4 Billion by 2020 53D Sensor Market Worth $3,319.71 Million by 2020 23D Sensor Market Worth $3,319.71 Million by 2020 33D Sensor Market Worth $3,319.71 Million by 2020 4
... 15-year study published in Acta Obstetricia et Gynecologica ... Societies of Obstetrics and Gynecology, indicate that human error ... birth. Inadequate fetal monitoring, lack of clinical skills, and ... often cited in Norwegian compensation claims following birth asphyxia. ...
... of people in a crowd, we could make on the fly ... person to pass through a turnstile. The latter resembles the model ... is able to detect the passage of individual DNA molecules through ... DNA molecules are diluted in a solution containing ions and are ...
... scientific team has discovered a gene associated with a ... variant may be an actual cause of this form ... children. "Because asthma is a complex disease, with ... recurrent asthma occurring between ages two and six," said ...
Cached Biology News:Human error most common cause of birth asphyxia 2Graphene nanoribbons for 'reading' DNA 2Novel gene variant found in severe childhood asthma 2
RayBio Human Cytokine Antibody Array 1.1 (4 array membranes) with Accessory, detects 20 cytokines (for lysate) Class: Antibody Array Products Product Group: Antibody Array...
Recombinant Feline IL-12/IL-23 p40...
Request Info...
Recombinant Equine IL-6...
Biology Products: